The ELBS pursues a holistic approach to tackle the challenges of clinical implementation in the liquid biopsy field. The network incorporates key players from academia, clinic, industry, and national government agencies to move this promising field forward collectively. Currently the focus of the ELBS is cancer; however, we are open to including additional liquid biopsy research fields in the future (e.g. cardiovascular or inflammatory diseases). We believe the success of reaching the overarching aim of clinical implementation relies on the accomplishment of the following objectives:
Encourage interactions between academia an industry
Intensive dialogue on critical issues of the field between the partners represents a crucial prerequisite to identify joint strategies and means of mutual support, thus, ensuring synergistic initiatives are embarked on that will end up driving the field forward. The ELBS allows for direct exchange between our members from leading academic institutions and industry partners via an extensive schedule of digital and in-person meetings. Also, the ELBS represents a pre-competitive arena for industry partners to test and refine their technologies, assays and pipelines through the feedback of top researchers of the field.
Disseminate the knowledge on liquid biopsy approaches and provide training
“Knowledge is like a garden, if it is not cultivated it cannot be harvested” (African Proverb). One of the missions of the ELBS is to educate on the opportunities but also limitations of the liquid biopsy field. Target audiences are researchers, the medical community, patient initiatives, and government agencies. This is implemented through presentations, training schools, and workshops. These efforts are spearheaded by the Dissemination/Education working group
Foster the introduction of LB into clinical trials
The ELBS wants to provide guidance for study coordinators and clinical experts wishing to integrate liquid biopsy approaches in their clinical trials. The vast landscape of existing technologies, assays, and available analytes can represent a substantial barrier when deciding on a suitable assay for a specific clinical question. The ELBS Work Group Clinical combines research with clinical experience to provide support of interventional clinical studies that determine the clinical utility of liquid biopsy as prerequisite for implementation into clinical practice.
Support liquid biopsy research
Research is the foundation on which all progress is based. The ELBS includes an ever-extending network of top basic and clinical researchers and academic institutions. We foster scientific exchange on pressing issues through various meetings focused either on specific topics and/or specific LB analytes (CTC, ctDNA, EV, etc.) Work Group Technology . Furthermore, the ELBS supports for research grant applications (e.g. by bringing together collaborators and further endorsement of its members).
Develop guidelines for research and clinical setting
Provide a partner for regulatory agencies, health care providers, and patient advocacy (PA) groups
To move LB assays towards clinical use, reimbursement is crucial. The ELBS represents an independent body and point of contact for regulatory agencies, health care providers, and PA groups.
Increase Europes visibility as a LB hub
Europe is the home of exceptional researchers, clinicians and companies of the LB field (see ESMO ctDNA guidelines, Ann. Oncol. 2022). It also has its own unique regulatory and public health system advantages and challenges. Thus, the ELBS provides a unique platform combining this knowledge and making this LB expertise visible within and beyond the EU. This makes ELBS also attractive for non-EU institutions.
Outreach and connection to other LB initiatives